PRNewswire

HONG KONG, Oct. 30, 2024 /PRNewswire/ — Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (AK117-302) for head and neck squamous cell carcinoma. This trial evaluates the innovative PD-1/VEGF

DURHAM, N.C., Oct. 30, 2024 /PRNewswire/ — Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced the resubmission of the new drug application (NDA) for the investigational product S

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: